The falling knife

Marcelo · 2026-02-09T15:17:49.997155Z

$OMDA Has anyone already pulled the ripcord or are you buying in installments?

jkb92@jkb92

9Mês

Probably also suffers from the Hims&Hers case...

•

3

•

Marcelo@Marcelo-80

9Mês

@jkb92 That is also my assumption, pre figures and outlook are actually good, which is why I got in. Since almost 1 month -35%

•

1

•

Get_Rich_or_Die_Tryin@Get_Rich_or_Die_Tryin

9Mês

I would have liked an explanation of the causal relationship 🤔

••

jkb92@jkb92

9Mês

@Get_Rich_or_Die_Tryin me too, is irrational

•

1

•

Fredi K.@equity_expert_1695

9Mês

@jkb92 According to your logic, you could call every share 😂

•

2

•

jkb92@jkb92

9Mês

@equity_expert_1695 If it was misleading, I would be happy to explain my logic again: In my opinion, both companies are being lumped together because of their platform character. And the overall mood is just bad because of Hims.

•

3

•

Get_Rich_or_Die_Tryin@Get_Rich_or_Die_Tryin

9Mês

@jkb92 so the platforms are so different that this connection makes absolutely no sense from my point of view.😂

•

1

•

jkb92@jkb92

9Mês

@Get_Rich_or_Die_Tryin I'm totally with you. I'm not saying that I see it that way. It's just my guess for the price drop.

•

1

•

Chris@Multibagger

9Mês

The stop worked for me today. It doesn't have to stay like this forever, but at the moment the health platform is not in demand thanks to the legally questionable methods of $HIMS.

•

1

•

Michey777@Michey777

9Mês

I bought more today. And to add to it again. The already published key data for 2025 were good, short quotas were reduced substantially. Tailwind from cheaper GLP1 drugs + need for advice from users. The company still has plenty of cash and is expected to be FCF positive in 2026. Valuation (if growth is only half as good as 2025, i.e. 20-25%) at 2 times sales is an absolute joke. But it is also a small stock, so such days are bitter, but still ok with a bit of cash in the back :)

•

1

•